As previously reported, Evercore ISI initiated coverage of Skye Bioscience (SKYE) with an Outperform rating and $10 price target Nimacimab is the “only weekly SC large molecule CB1 inhibitor in development,” says the analyst, who sees the drug having the potential to “fill critical gaps in obesity care.” The 26-week Phase 2a readout due in late Q3 or early Q4 will be “the next major test,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience initiated with an Outperform at Evercore ISI
- Skye Bioscience Earnings Call: Positive Outlook Amid Challenges
- Skye Bioscience Releases Q2 2025 Financial Results
- Skye Bioscience debuts ‘Anatomy of Progress’ nimacimab development update series
- Skye Bioscience participates in panel at Evercore obesity event